Penile Cancer

Penile cancer is a relatively rare cancer that can seriously affect penile tissue. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we can provide the best vaccine development services for penile cancer.

Introduction to Penile Cancer

Penile cancer is a rare cancer that primarily affects the skin of the penis and the prepuce (the skin that covers the head of the penis). It is most common in men over the age of 50. Most penile cancers affect the skin covering the penis (prepuce) or the head or tip of the penis (glans).

Traditional Therapy for Penile Cancer

Therapy of early-stage cancer often involves non-surgical therapies, such as chemotherapy creams such as 5-fluorouracil (5-FU) and laser therapy. If the cancer is found late, therapy may include surgery, chemotherapy, and radiation.

Fig. 1 Immune-based therapies for penile cancer. (Tang, Y., et al., 2022)

Penile Cancer Vaccine

About half of all penile cancers are caused by certain viruses called human papillomavirus (HPV). The HPV vaccine, as a preventive vaccine, can be used to reduce the risk of penile cancer to some extent. But for penile cancer that has already occurred, innovative new therapies are still needed, such as therapeutic penile cancer vaccines.

Due to the complexity of the tumor microenvironment in penile cancer, the immune system exhibits tolerance and is limited by polarization mechanisms, thereby maintaining or worsening the disease. Therefore, therapeutic vaccines must be able to effectively activate the immune system, thereby delivering concentrated antigens to human leukocyte antigen (HLA) class I and II molecules in DC, promoting CD4 and CD8 T cell responses. The best vaccine platforms include DNA and RNA vaccines, as well as synthetic peptides.

Our Service

Against penile cancer, Alfa Cytology offers a variety of penile cancer vaccine development services, such as peptides, DNA, RNA, or viral vectors. In addition to overall vaccine development, we also provide tumor antigen identification services, adjuvant selection services, and delivery system adaptation services for penile cancer. The molecular biology and immunology technology platform of Alfa Cytology helps to identify vaccine formulations that are best suited to cancer immunotherapies.

The development of penile cancer vaccines also requires preclinical evaluation to determine their safety and efficacy. Alfa Cytology is committed to the research and development of therapeutic cervical cancer vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.